Alcohol and GLP-1 medications

What the official documents say

We searched the full US prescribing information of each medicine, including the Medication Guides and Instructions for Use, the MedlinePlus pages and, for Mounjaro®, the EU product information. No document gives guidance about drinking: there is no warning, no limit and no statement that it is safe.

The one mention we found

MedlinePlus, the patient information service of the US National Library of Medicine, has a page for each medicine. The semaglutide and tirzepatide pages do not mention alcohol ^[9][10]. The liraglutide page, in its list of things to tell your doctor before you start, asks you to mention heavy drinking, whether current or in the past ^[8].

That is the full extent of what these sources say. Because they are silent, any specific rule you read elsewhere, such as a number of drinks or a waiting time after your dose, does not come from the label. Your prescriber can give advice that takes your own health into account.

What studies report about GLP-1 medicines and drinking

Several trials have tested GLP-1 medicines in people with alcohol use disorder, a diagnosis rather than occasional social drinking. The largest so far, published in The Lancet in 2026, randomized 108 treatment-seeking adults with alcohol use disorder and obesity to weekly semaglutide or placebo for 26 weeks, both alongside cognitive behavioural therapy. Heavy drinking days fell by 41.1 percentage points with semaglutide and 26.4 with placebo; stomach side effects were more common with semaglutide ^[12].

The overall picture is still mixed. A 2025 meta-analysis pooling three earlier randomized trials found reductions in drinking and craving that did not reach statistical significance, while six observational studies linked GLP-1 use with fewer alcohol-related events ^[13]. Observational studies cannot show cause and effect, and none of the US labels lists alcohol use disorder as an approved use ^[1][3][13].

Why a drink may feel different

The labels do not discuss this, so the evidence is thin and comes in layers. What the labels do establish is that these medicines slow stomach emptying; the Mounjaro® label says the delay is largest after the first dose and lessens over time ^[1].

A 2025 pilot study gave a standard alcoholic drink to 20 adults with obesity, half of them on a GLP-1 medicine. In that group, breath alcohol and the subjective effects rose more slowly, and nausea did not account for it ^[14]. The authors suggest slower absorption as one possible reason people on these medicines drink less, but a study this small and non-randomized cannot confirm it or say how you will feel.

Low blood sugar

The labels warn that low blood sugar is more likely when a GLP-1 is used with insulin or a sulfonylurea, a medicine that makes the pancreas release insulin ^[1][4]. The Medication Guides list signs such as dizziness, sweating, shakiness, confusion or drowsiness, hunger, a fast heartbeat and blurred vision, and ask you to talk to your provider about how to recognise and treat it ^[3].

The NIDDK adds the alcohol side of the picture: drinking too much without enough food makes it harder for the body to keep blood glucose steady and can stop you noticing the first symptoms, and it notes that eating when you drink is safer ^[11]. If you have type 2 diabetes and use insulin or a sulfonylurea, how drinking fits your blood sugar plan is a specific question for your prescriber.

Fluids and stomach side effects

Nausea, vomiting and diarrhoea are among the most common side effects in the labels, and the Wegovy® Medication Guide explains that losing fluids this way can lead to kidney problems ^[3]. It says drinking fluids helps lower the chance of dehydration, and asks you to tell your provider promptly if these symptoms keep going ^[3].

If you notice that some evenings are followed by more stomach trouble, that pattern is worth writing down and showing your clinician.

Pancreas and gallbladder warnings

• Pancreatitis: the Medication Guides describe severe stomach pain that does not go away, sometimes felt through to the back, with or without nausea or vomiting, and ask you to stop the medicine and call your provider straight away ^[3].
• Gallbladder problems: pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-coloured stools are listed as reasons to call your provider ^[3].
• The MedlinePlus pages for semaglutide and liraglutide also ask you to tell your doctor before starting if you have had pancreatitis or gallbladder disease ^[8][9].
• The warnings themselves do not mention alcohol. The one label link we found is in the Victoza® trial results, which note that some people who developed pancreatitis had other risk factors such as gallstones or alcohol abuse ^[16]. MedlinePlus asks about heavy drinking and past pancreatitis in the same list for liraglutide ^[8].

Questions to ask your prescriber

• Is drinking alcohol reasonable for me on this medicine, and if so, how much?
• Does my answer change while my dose is being increased?
• I take insulin or a sulfonylurea: what should I know about drinking and low blood sugar?
• Which symptoms after a night out should make me call you?
• Does anything in my history, such as pancreatitis or past heavy drinking, change your advice?
• I want to cut down on drinking: is that something to discuss alongside my GLP-1 treatment?

Ozempic®, Wegovy®, Rybelsus®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and KwikPen® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help